Lipid Disorder Treatment Market: by Drug Type (Pravastatin, Simvastatin, Rosuvastatin, Fluvastatin, Atorvastatin and Other Drugs); by Indication (Heterozygous Familial Hypercholesterolemia, Familial Hypertriglyceridemia, Familial Dysbetalipoproteinemia, Familial Defective Apolipoprotein B-100, Familial Combined Hyperlipidemia and Other Indications); by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies)-Global Industry Analytics, COVID-19 Business Impact, and Trends, 2020 - 2029

                                          
Abstract


The report covers forecast and analysis for the lipid disorder treatment market on a global and regional level. The study provides historic data from 2016 along with forecast from 2021 to 2026 based on revenue (USD Million). The study includes drivers and restraints for the lipid disorder treatment market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the lipid disorder treatment market on a global as well as regional level.

According to the report, global demand for lipid disorder treatment market was valued at approximately USD 22.42 billion in 2018, and is expected to generate revenue of around USD 38.04 billion by end of 2025, growing at a CAGR of around 7.9% between 2019 and 2025.

In order to give the users of this report a comprehensive view on the lipid disorder treatment market we have included competitive landscape and analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the lipid disorder treatment market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new drug type launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved in the lipid disorder treatment market on global and regional basis.

Lipid disorder includes a broad range of metabolic conditions that affect lipid levels in the blood. Lipid disorders are usually characterized by increased levels of cholesterol, lipoproteins and/or triglycerides in the blood which may relate to increased risk of cardiovascular disease. Most of these disorders are acquired through sedentary lifestyle, obesity, alcoholism, inactivity and lack of exercise. The risk due to congenital causes is less common. Blood lipid profile includes triglycerides, HDL, LDL and total cholesterol. Lipid disorder management and treatment involves use of lipid lowering agents (mainly use of statins) and lifestyle modifications.

The demand for lipid disorder treatment market is driven by increasing prevalence of LDL and triglyceride associated lipid disorders, growing prevalence of cardiovascular diseases, changing eating habits and sedentary lifestyle across the globe. Also, focus of major players on development of novel treatment options, increasing geriatric population and increasing health awareness are other factors that boost the market growth. Emerging markets with large population base and increasing geriatric population are expected to bring new growth opportunities for major market players operating in the global lipid disorder treatment.

Based on drug type, global lipid disorder treatment market is bifurcated into pravastatin, simvastatin, rosuvastatin, fluvastatin, atorvastatin and other drugs. Atorvastatin drug type segment accounted for largest market share in 2018 whereas rosuvastatin segment is expected to witness rapid CAGR over the forecast period. Effectiveness of atorvastatin against bad cholesterol has led to their increased use for treating cardiovascular disorders and reducing triglyceride levels and thus account for largest market share.

Based on indication market is segmented into heterozygous familial hypercholesterolemia, familial hypertriglyceridemia, familial dysbetalipoproteinemia, familial defective apolipoprotein b-100, familial combined hyperlipidemia and other indications.

The distribution channel segment is divided Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Retail pharmacies segment held largest market share due to high number of retail pharmacies across the globe. Online pharmacies will witness rapid growth over the forecast period.

North America dominated the global lipid disorder treatment market in 2018. The increasing prevalence of lipid disorders, increasing risk of related cardiovascular diseases, and growing awareness are factors driving the market in this region. Europe was the second-largest regional market. The presence of developed infrastructure and increasing awareness and prevalence of lipid disorders are some of factors that boost market growth in this region. Latin America is expected to witness moderate growth over the forecast period. Asia Pacific region will exhibit the highest growth for lipid disorder treatment market in the coming years. The increasing geriatric population base with high vulnerability to metabolic disorders, sedentary lifestyle, growing prevalence of lipid disorders are factors promoting lipid disorder treatment market growth in Asia Pacific. Middle East and Africa will see considerable growth in coming years.

Major players included in the report are Mylan Pharmaceuticals, Teva Pharmaceuticals, Kowa Pharmaceuticals America, Inc., Novartis AG, Pfizer, Inc., AstraZeneca Plc, Sun Pharmaceuticals Industries Ltd., Glenmark Pharmaceuticals Ltd., Wockhardt Limited, Emcure Pharmaceuticals Ltd., Ranbaxy Inc., Mylan Institutional, Lupin Pharmaceuticals, Inc.

and Merck & Co. among others.

The report segment of global lipid disorder treatment market as follows:

Global Lipid Disorder Treatment Market: By Drug Type

  
Atorvastatin
  
Fluvastatin
  
Rosuvastatin
  
Simvastatin
  
Pravastatin
  
Other Drugs

Global Lipid Disorder Treatment Market: By Indication

  
Heterozygous Familial Hypercholesterolemia
  
Familial Hypertriglyceridemia
  
Familial Dysbetalipoproteinemia
  
Familial Defective Apolipoprotein B-100
  
Familial Combined Hyperlipidemia
  
Other Indications

Global Lipid Disorder Treatment Market: By Distribution Channel

  
Hospital Pharmacies
  
Retail Pharmacies
  
Online Pharmacies

Introduction to Atorvastatin(Lipitor®)

Atorvastatin is used together with diet, weight loss, and exercise to reduce the risk of heart attack and stroke and to decrease the chance that heart surgery will be needed in people who have heart disease or who are at risk of developing heart disease. This a lipid-lowering drug is included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase,8 which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL).

Atorvastatin is also used to decrease the amount of fatty substances such as low-density lipoprotein (LDL) cholesterol (bad cholesterol) and triglycerides in the blood and to increase the amount of high-density lipoprotein (HDL) cholesterol (good cholesterol) in the blood. Atorvastatin may also be used to decrease the amount of cholesterol and other fatty substances in the blood in children and teenagers 10 to 17 years of age who have familial heterozygous hypercholesterolemia (an inherited condition in which cholesterol cannot be removed from the body normally). Atorvastatin is in a class of medications called HMG-CoA reductase inhibitors. It works by slowing the production of cholesterol in the body to decrease the amount of cholesterol that may build up on the walls of the arteries and block blood flow to the heart, brain, and other parts of the body.

Introduction to Fluvastatin

Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin.

Fluvastatin, the first synthetically-derived HMG-CoA reductase inhibitor, is a hydrophilic, acidic, antilipemic agent used to lower cholesterol and triglyceride levels associated with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb), to slow the progression of coronary atherosclerosis in patients with CHD and as secondary prevention therapy in patients with CHD to reduce the risk of requiring coronary revascularization procedures.

Introduction to Rosuvastatin

Rosuvastatin also known as the brand name product Crestor, is a lipid-lowering medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.

Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to atorvastatin, lovastatin, and simvastatin, which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as ciclosporin, gemfibrozil, and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.

The Health Canada monograph for rosuvastatin further specifies that rosuvastatin is indicated for the reduction of elevated total cholesterol (Total-C), LDL-C, ApoB, the Total-C/HDL-C ratio and triglycerides (TG) and for increasing HDL-C in hyperlipidemic and dyslipidemic conditions when response to diet and exercise alone has been inadequate.

Introduction to Simvastatin

Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver.

Introduction to Pravastatin

Pravastatin is the 6-alpha-hydroxy acid form of mevastatin.11 Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug.10 This drug was developed by Sankyo Co. Ltd.; however, the first approved pravastatin product was developed by Bristol Myers Squibb and FDA approved in 1991.

Pravastatin is made through a fermentation process in which mevastatin is first obtained. The manufacturing process is followed by the hydrolysis of the lactone group and the biological hydroxylation with Streptomyces carbophilus to introduce the allylic 6-alcohol group.

Global Lipid Disorder Treatment Market: By Region

North America

  
U.S.

Europe

  
UK
  
France
  
Germany

Asia Pacific

  
China
  
Japan
  
India
  
Indonesia
  
South Korea
  
Australia

Latin America

  
Argentina
  
Brazil
  
Portugal
  
Mexico

Middle East and Africa